Cresilon Achieves Recognition in Fast Company's 50 Most Innovative Companies of 2026

Cresilon, a pioneering biotechnology company based in Brooklyn, has made headlines by being included in Fast Company's esteemed list of the World's 50 Most Innovative Companies for 2026. Ranking at the top in the medical devices category and standing at number 46 overall, this notable acknowledgment is a testament to the company’s relentless pursuit of innovation in trauma care.

This marks the second occasion that Cresilon has clinched the top position in the medical devices segment, reflecting the significant progress it has made since it was first recognized in 2024. Joe Landolina, Cresilon's co-founder and CEO, highlighted the company's commitment by stating, "Being named one of the World's 50 Most Innovative Companies and ranked No. 1 in medical devices again speaks to the work our team is doing every day."

Cresilon commenced its journey with the vision of saving lives, and the introduction of their cutting-edge product, TRAUMAGEL, has been a game changer in emergency medical response. The hemostatic technology aims to effectively manage bleeding, a critical factor in trauma cases. Since its introduction, TRAUMAGEL has touched countless lives, with reports indicating that it saved at least one life per day on average in 2025 alone.

TRAUMAGEL received FDA clearance in August 2024 and was rolled out nationwide by January 2025, making it widely available for use by first responders and in hospitals across the United States. Its critical role in mitigating severe blood loss, which causes over 35% of prehospital death cases, has established its reputation as an essential tool in emergency care.

By the end of 2025, TRAUMAGEL had been deployed in all primary care environments, including law enforcement, fire services, emergency medical services, and hospital trauma teams. The product is under evaluation by the U.S. military and has been field-tested in selected units, a promising expansion for its use.

To meet the growing demand and support its ambitions, Cresilon has fortified its manufacturing capabilities, increasing its footprint to 55,000 square feet at a state-of-the-art biomanufacturing facility in Brooklyn. This development not only marks a milestone for Cresilon but also highlights the overarching potential for innovation in the medical device sector.

The accolade from Fast Company is part of its acclaimed franchise that annually showcases businesses that are revolutionizing their respective industries through innovation. This year, thousands of companies were considered for recognition, emphasizing the competitive nature of this honor. Brendan Vaughan, editor-in-chief of Fast Company, stated, "Our list of the Most Innovative Companies is about spotlighting organizations that don't just adapt to change. They drive it," reinforcing the significance of recognition for companies like Cresilon.

As we look toward the future, Cresilon remains steadfast in its mission to save lives through technological advancements. The full list of honorees from Fast Company will be available on newsstands starting March 31, 2026, highlighting the impressive achievements of businesses redefining their sectors with creativity and innovation.

About Cresilon: Cresilon® specializes in the development, manufacture, and marketing of hemostatic medical devices utilizing proprietary hydrogel technology. Their plant-based solutions enable rapid control of bleeding, significantly impacting trauma care and animal health. Cresilon's vision is to enhance life-saving medical interventions while contributing to the broader field of biotechnology. For more information, visit Cresilon's website.